Navarro DDA, Mili AT

Language: Spanish
References: 0
Page: 1-10
PDF size: 90.27 Kb.

ABSTRACT

Introduction: treatment with bisphosphonates is effective to prevent bone fractures due to fragility.
Objectives: to describe the bone response to bisphosphonate treatment in middle aged women with osteoporosis and some clinical factors related to it.
Methods: retrospective study covering the total number of women aged 40-59 years with osteoporosis, who were seen at the climaterium and osteoporosis clinic from 2005 to 2010 and treated with alendromate (70 mg a week) or ibandronate (150 mg a month) for over a year and who underwent annual densitometries. Bone response was considered as favorable when there was no loss of bone mineral density nor new fractures, and unfavorable when there was loss of bone mineral density and/or new fractures occurred. The most important associated factors were age, race, family and personal history of osteoporosis, smoking, time of reproductive life, the phase of climaterium and the type of bisphosphonates taken. Average frequency distribution and standard deviation were used along with U Mann Whitney test with (p< 0.05) for statistical significance to establish associations.
Results: alendronate was taken by 53 patients, ibandronate by three and the combination of alendronate and ibandronate by 12 patients. In the sample 98.5 % adhered to treatment for 3 to 5 years. Favorable bone response was seen in 86.7 % (59 out of 68) and the related factors were no family history of osteoporosis, breastfeeding and taking alendronate. Unfavorable response was seen in 9 out of 68 and occurred in smoking women who had family history of osteoporosis and took ibandronate (8 out of 9).
Conclusions: usefulness of alendronate is confirmed to preserve bone mass in lumbar column.